Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026

Résumé détaillé

In a post hoc analysis of the phase 3 REDEFINE 1 trial, 67.8% of adults treated with investigational CagriSema 2.4 mg / 2.4 mg were early responders, achieving at least 5% weight…

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 15, 2026 /PRNewswire/ -- Today, Novo Nordisk announced results from two post hoc analyses of the phase 3 REDEFINE 1 trial of investigational CagriSema 2.4 mg / 2.4 mg, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. The analyses provide further insight into differences in individual patterns of weight loss, including early treatment response, as well as participants' reported physical and psychosocial effects of weight. Results were presented at ObesityWeek® 2026 in Washington, DC, US.1,2

"Obesity is a chronic disease, and people respond to treatment differently and over different timeframes," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. "That is why we continue to study the REDEFINE 1 data in greater depth. In this post hoc analysis, most people treated with CagriSema 2.4 mg / 2.4 mg were early responders, meaning they lost at least 5% of their body weight within the first 8 weeks of treatment. Together with the patient-reported physical function results, this research adds to the growing evidence base from the REDEFINE clinical program."

Early response and weight loss trajectories (post hoc analysis)In this post hoc analysis, 67.8% of CagriSema-treated participants were early responders (at least 5% weight loss at week 8). Observed mean weight loss at week 68 was 25.4% among early responders. Among delayed responders, observed mean weight loss at week 68 was 17.8%.‡ Women were more likely to be early responders than delayed responders (71.8% vs 59.5%).1

Weight loss by early response status with CagriSema 2.4 mg / 2.4 mg in REDEFINE 1 (post hoc analysis; observed data‡)1

‡Observed data from the on-treatment period; post hoc analysis, hypothesis-generating.

"In clinical practice, it can be hard to know early on how an individual patient will respond…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.